S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.57%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.57%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.57%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.57%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)

IN8bio Stock Price, News & Analysis (NASDAQ:INAB)

$0.83
+0.05 (+6.87%)
(As of 04:00 PM ET)
Compare
Today's Range
$0.77
$0.88
50-Day Range
$0.69
$1.23
52-Week Range
$0.65
$3.95
Volume
308,402 shs
Average Volume
1.13 million shs
Market Capitalization
$26.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

IN8bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,220.8% Upside
$11.00 Price Target
Short Interest
Healthy
0.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of IN8bio in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$2,375 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.93) to ($0.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

99th out of 949 stocks

Biological Products, Except Diagnostic Industry

13th out of 157 stocks


INAB stock logo

About IN8bio Stock (NASDAQ:INAB)

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

INAB Stock Price History

INAB Stock News Headlines

The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
IN8bio GAAP EPS of -$0.23
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
IN8bio Inc Ordinary Shares INAB
IN8bio director Graff Jeremy acquires 2,500 company shares
IN8bio (INAB) Gets a Buy from H.C. Wainwright
Mizuho Securities Sticks to Their Buy Rating for IN8bio (INAB)
See More Headlines
Receive INAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INAB
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$14.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+1,311.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-28,520,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.56 per share

Miscellaneous

Free Float
21,434,000
Market Cap
$24.93 million
Optionable
Not Optionable
Beta
-0.22
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Tai-Wei Ho (Age 46)
    Co-Founder, President, CEO & Director
    Comp: $837k
  • Dr. Kate Rochlin Ph.D. (Age 42)
    Chief Operating Officer
    Comp: $565.4k
  • Dr. Trishna Goswami M.D. (Age 45)
    Chief Medical Officer
    Comp: $638.51k
  • Dr. Lawrence S. Lamb Ph.D. (Age 69)
    Executive VP, Co-Founder & Chief Scientific Officer
    Comp: $482.47k
  • Mr. Patrick McCall CPA (Age 40)
    CFO & Secretary
    Comp: $519.35k














INAB Stock Analysis - Frequently Asked Questions

Should I buy or sell IN8bio stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IN8bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INAB shares.
View INAB analyst ratings
or view top-rated stocks.

What is IN8bio's stock price target for 2024?

2 brokerages have issued 12 month price targets for IN8bio's stock. Their INAB share price targets range from $8.00 to $14.00. On average, they anticipate the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 1,220.8% from the stock's current price.
View analysts price targets for INAB
or view top-rated stocks among Wall Street analysts.

How have INAB shares performed in 2023?

IN8bio's stock was trading at $2.31 at the beginning of 2023. Since then, INAB stock has decreased by 63.9% and is now trading at $0.8328.
View the best growth stocks for 2023 here
.

Are investors shorting IN8bio?

IN8bio saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 27,600 shares, a decrease of 51.0% from the October 31st total of 56,300 shares. Based on an average daily trading volume, of 108,700 shares, the short-interest ratio is presently 0.3 days. Approximately 0.1% of the company's stock are sold short.
View IN8bio's Short Interest
.

When is IN8bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our INAB earnings forecast
.

How were IN8bio's earnings last quarter?

IN8bio, Inc. (NASDAQ:INAB) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.11.

When did IN8bio IPO?

(INAB) raised $44 million in an IPO on Friday, July 30th 2021. The company issued 4,000,000 shares at a price of $10.00-$12.00 per share. B. Riley Securities served as the underwriter for the IPO.

Who are IN8bio's major shareholders?

IN8bio's stock is owned by many different institutional and retail investors. Top institutional investors include Voss Capital LLC (1.62%) and Rock Creek Group LP (0.47%). Insiders that own company stock include Emily Fairbairn, Jeremy R Graff, Kate Rochlin, Lawrence Lamb, Patrick Mccall, Trishna Goswami and William Tai-Wei Ho.
View institutional ownership trends
.

How do I buy shares of IN8bio?

Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:INAB) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -